Psychedellic Assisted Psychotherapy - an Interview with Alexa Altman, Ph.D. - Ep 677

Dr. Reedy welcomes Dr. Alexa Altman where she discusses how psychedelics bring the unconscious material into consciousness. She talks about the importance of integration. Dr. Altman’s Website: https://www.i-psychedelic.com 1. Single-dose psilocybin (25 mg) with psychological support for MDDJAMA – “Single-Dose Psilocybin Treatment for Major Depressive Disorder” psychiatryonline.org+15sunstonetherapies.com+15pmc.ncbi.nlm.nih.gov+15 Summary: Demonstrated strong antidepressant effects and good tolerability over follow-up. Email: info@hopkinspsychedelic.org 2. One-Year Follow-Up of Psilocybin for Depression Study: Long-term effects of psilocybin therapy for depression Johns Hopkins – “Psilocybin treatment for major depression effective for up to a year” Summary: 67% of participants remained in remission one year post-treatment. 3. MDMA-Assisted Therapy for Severe PTSD Randomized, placebo-controlled MDMA-assisted therapy Nature Medicine – “MDMA-assisted therapy for severe PTSD” Summary: Significant reduction in PTSD symptoms, well‑tolerated in a diverse cohort. Contact (MAPS / Lykos Therapeutics): Email: info@maps.org 4. Psilocybin for Cancer-Related Anxiety & Depression Psilocybin in patients with life-threatening cancer PMC – “High-dose psilocybin produced large decreases in depressed mood and anxiety…” Summary: 80% of participants maintained significant symptom relief at 6 months. Website: heffter.org (contact via site) en.wikipedia.org 1. Johns Hopkins University Center for Psychedelic and Consciousness Research Psilocybin for depression, anxiety, addiction, and end-of-life distress Why it’s top-tier: The first major U.S. institution to receive regulatory approval for psychedelic research in modern times. 🔗 hopkinspsychedelic.org 2. Imperial College London Centre for Psychedelic Research Psilocybin for treatment-resistant depression, brain imaging, DMT studies Why it’s top-tier: Home of pioneering neuroimaging studies on psychedelics; led by Robin Carhart-Harris (now at UCSF). 🔗 imperial.ac.uk 3. Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA for PTSD (now in Phase 3 trials), harm reduction, global education Why it’s top-tier: MAPS initiated the first FDA-approved Phase 3 trials for MDMA-assisted therapy. 🔗 maps.org 4. University of California, San Francisco Psychedelic Research Program Psilocybin, DMT, ibogaine; Robin Carhart-Harris now leads U.S. arm Why it’s top-tier: Integrates neuroscience, clinical psychology, and pharmacology. 🔗 psychedelics.ucsf.edu 5. NYU Langone Health Center for Psychedelic Medicine End-of-life anxiety, alcoholism, PTSD, and psilocybin studies Why it’s top-tier: Known for rigorous clinical trials and major collaborations. 🔗 med.nyu.edu 6. University of California, Los Angeles UCLA Psychedelic Studies Initiative Psilocybin + CBT, anxiety, clinical protocols Why it’s top-tier: Conducting one of the few FDA-regulated psilocybin trials with integrated therapy. 🔗 uclapsi.org 7. University of Wisconsin–Madison / Usona Institute Psilocybin for major depression (FDA Phase 3 trials) Why it’s top-tier: Leading U.S.-based nonprofit with regulatory traction and major academic partnerships. 🔗 usonainstitute.org 8. Massachusetts General Hospital / Harvard Medical School Center for the Neuroscience of Psychedelics Neurobiological mechanisms of psychedelics Why it’s top-tier: Combines Harvard academic leadership with Mass General clinical infrastructure. 🔗 massgeneral.org 9. University of New Mexico Psychedelic-Assisted Therapies & Research Group Ketamine, DMT, and MDMA research; Indigenous-informed approaches Why it’s top-tier: Interdisciplinary and trauma-informed program with cultural awareness. 🔗 hsc.unm.edu 10. Oregon Health & Science University State-licensed psilocybin therapy programs, public health, training Why it’s top-tier: One of the first institutions engaging with psilocybin therapy post-legalization under Measure 109. 🔗 ohsu.edu